Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 6, Issue 262, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3009940
Keywords
-
Categories
Funding
- Lundbeck Foundation
- Danish Free Research Councils
- Novo Nordisk Foundation
- European Union Seventh Framework Programme-Health Program Evolution and Transfer of Antibiotic Resistance [282004]
- U.S. NIH [1DP5OD009172-01]
- Lundbeck Foundation [R140-2013-13496, R77-2010-6772] Funding Source: researchfish
- Novo Nordisk Fonden [NNF13SA0006019, NNF13SA0009311, NNF14OC0011335, NNF10CC1016517] Funding Source: researchfish
Ask authors/readers for more resources
Resistance arises quickly during chemotherapeutic selection and is particularly problematic during long-term treatment regimens such as those for tuberculosis, HIV infections, or cancer. Although drug combination therapy reduces the evolution of drug resistance, drug pairs vary in their ability to do so. Thus, predictive models are needed to rationally design resistance-limiting therapeutic regimens. Using adaptive evolution, we studied the resistance response of the common pathogen Escherichia coli to 5 different single antibiotics and all 10 different antibiotic drug pairs. By analyzing the genomes of all evolved E. coli lineages, we identified the mutational events that drive the differences in drug resistance levels and found that the degree of resistance development against drug combinations can be understood in terms of collateral sensitivity and resistance that occurred during adaptation to the component drugs. Then, using engineered E. coli strains, we confirmed that drug resistancemutations that imposed collateral sensitivity were suppressed in a drug pair growth environment. These results provide a framework for rationally selecting drug combinations that limit resistance evolution.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available